THIAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Thiamine Hydrochloride, and when can generic versions of Thiamine Hydrochloride launch?
Thiamine Hydrochloride is a drug marketed by Abraxis Pharm, Bel Mar, Caplin, Dell Labs, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hospira, Luitpold, Mylan Institutional, Parke Davis, Sagent Pharms Inc, Watson Labs, West-ward Pharms Int, and Wyeth Ayerst. and is included in seventeen NDAs.
The generic ingredient in THIAMINE HYDROCHLORIDE is thiamine hydrochloride. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the thiamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thiamine Hydrochloride
A generic version of THIAMINE HYDROCHLORIDE was approved as thiamine hydrochloride by WEST-WARD PHARMS INT on December 31st, 1969.
Summary for THIAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 16 |
NDAs: | 17 |
Finished Product Suppliers / Packagers: | 12 |
Raw Ingredient (Bulk) Api Vendors: | 140 |
Clinical Trials: | 82 |
Patent Applications: | 2,150 |
Formulation / Manufacturing: | see details |
DailyMed Link: | THIAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for THIAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hamilton Health Sciences Corporation | Phase 3 |
Population Health Research Institute | Phase 3 |
Canadian Institutes of Health Research (CIHR) | Phase 3 |